# Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258

> **NCT01440959** · PHASE2 · COMPLETED · sponsor: **Asan Medical Center** · enrollment: 30 (actual)

## Conditions studied

- Gastrointestinal Stromal Tumors

## Interventions

- **DRUG:** dovitinib

## Key facts

- **NCT ID:** NCT01440959
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2020-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01440959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01440959, "Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01440959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*